Where Are We With Adjuvant Therapy of Stage III and IV Melanoma in 2009?

Authors: Leslie A. Fecher MD1 and Keith T. Flaherty MD1
View More View Less
  • 1 Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania

Adjuvant therapy options for advanced melanoma in 2009 remain active observation, high-dose interferon, or clinical trial participation. Close observation is currently the only required adjuvant management, with the purpose of detecting the emergence of regional or metastatic disease early, when surgical management may still be possible. The National Comprehensive Cancer Network guidelines for the workup and follow-up of all stages of melanoma must be tailored to specific patients by the treating physician. This article explores the factors to consider when individualizing care within the scope of these guidelines.

Correspondence: Leslie Fecher, MD, 3400 Spruce Street, 16 Penn Tower, Philadelphia, PA 19104. E-mail: leslie.fecher@uphs.upenn.edu
  • 1

    Stedman’s Medical Dictionary, 27th ed. Baltimore: Lippincott Williams & Wilkins; 2003.

  • 2

    Jemal A, Siegel R, Ward E et al.. Cancer statistics, 2008. CA Cancer J Clin 2008;58:7196.

  • 3

    Coit D, Houghton A, Akerley W et al.. NCCN Clinical Practice Guidelines in Oncology: Melanoma. NCCN Practice Guidelines in Oncology, Version 2, 2008. Available at: http://www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf. Accessed January 20, 2009.

    • Search Google Scholar
    • Export Citation
  • 4

    Balch C, Buzaid A, Soong S et al.. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635648.

    • Search Google Scholar
    • Export Citation
  • 5

    Ben-Porat L, Panageas K, Hanlon C et al.. Estimates of stage-specific survival are altered by changes in the 2002 AJCC staging system for melanoma. Cancer 2006;106:163171.

    • Search Google Scholar
    • Export Citation
  • 6

    Roberts A, Cochran A. Pathologic analysis of sentinel lymph nodes in melanoma patients: current and future trends. J Surg Oncol 2004;85:152161.

    • Search Google Scholar
    • Export Citation
  • 7

    de Wilt J, van Akkooi A, Verhoef C et al.. Detection of melanoma micrometastases in sentinel nodes—the cons. Surg Oncol 2008;17:175181.

  • 8

    Essner R, Lee J, Wanek L et al.. Contemporary surgical treatment of advanced-stage melanoma. Arch Surg 2004;139:961967.

  • 9

    Neuman H, Patel A, Hanlon C et al.. Stage-IV melanoma and pulmonary metastases: factors predictive of survival. Ann Surg Oncol 2007;14:28472853.

  • 10

    Kirkwood J, Strawderman M, Ernstoff M et al.. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:717.

    • Search Google Scholar
    • Export Citation
  • 11

    Kirkwood J, Manola J, Ibrahim J et al.. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004;10:16701677.

    • Search Google Scholar
    • Export Citation
  • 12

    Kirkwood J, Ibrahim J, Sondak V et al.. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18:24442458.

    • Search Google Scholar
    • Export Citation
  • 13

    Kirkwood J, Ibrahim J, Sosman J et al.. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:23702380.

    • Search Google Scholar
    • Export Citation
  • 14

    Eggermont A, Suciu S, Ruka W et al.. EORTC 18961: postoperative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II melanoma: 2nd interim analysis led to an early disclosure of the results [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 9004.

    • Search Google Scholar
    • Export Citation
  • 15

    Moschos S, Edington H, Land S et al.. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 2006;24:31643171.

    • Search Google Scholar
    • Export Citation
  • 16

    Hauschild A, Gogas H, Tarhini A et al.. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer 2008;112:982994.

    • Search Google Scholar
    • Export Citation
  • 17

    Grob JJ, Dreno B, de la Salmoniere P et al.. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 1998;351:19051910.

    • Search Google Scholar
    • Export Citation
  • 18

    Cascinelli N, Belli F, MacKie R et al.. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 2001;358:866869.

    • Search Google Scholar
    • Export Citation
  • 19

    Hauschild A, Volkenandt M, Tilgen W et al.. Efficacy of interferon alpha 2a in 18 vs. 60 months of treatment in patients with primary melanoma of ≥ 1.5 mm tumor thickness: a randomized phase III DeCOG trial [abstract]. J Clin Oncol 2008;26:Abstract 9032.

    • Search Google Scholar
    • Export Citation
  • 20

    Garbe C, Radny P, Linse R et al.. Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol 2008;19:11951201.

    • Search Google Scholar
    • Export Citation
  • 21

    Bukowski R, Tendler C, Cutler D et al.. Treating cancer with PEG intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation. Cancer 2002;95:389396.

    • Search Google Scholar
    • Export Citation
  • 22

    Eggermont A, Suciu S, Santinami M et al.. Adjuvant therapy with pegylated interferon alfa-2b vs. observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008;372:117126.

    • Search Google Scholar
    • Export Citation
  • 23

    Creagan E, Dalton R, Ahmann D et al.. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995;13:27762783.

    • Search Google Scholar
    • Export Citation
  • 24

    Gogas H, Dafni U, Bafaloukos D et al.. A randomized phase III trial of 1 month vs. 1 year adjuvant high-dose interferon alfa-2b in patients with resected high risk melanoma [abstract]. J Clin Oncol 2007;25:Abstract 8505.

    • Search Google Scholar
    • Export Citation
  • 25

    Anaya D, Xing Y, Feng L et al.. Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease. Cancer 2008;112:20302037.

    • Search Google Scholar
    • Export Citation
  • 26

    McMasters KM, Ross MI, Reintgen DS et al.. Final results of the Sunbelt Melanoma Trial [abstract]. J Clin Oncol 2008;26:Abstract 9003.

  • 27

    Wheatley K, Ives N, Hancock B et al.. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 2003;29:241252.

    • Search Google Scholar
    • Export Citation
  • 28

    Verma S, Quirt I, McCready D et al.. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 2006;106:14311442.

    • Search Google Scholar
    • Export Citation
  • 29

    Wheatley K, Ives N, Eggermont A et al.. Interferon-alfa as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials [abstract]. J Clin Oncol 2007;25:Abstract 8526.

    • Search Google Scholar
    • Export Citation
  • 30

    Kilbridge K, Weeks J, Sober A et al.. Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol 2001;19:812823.

  • 31

    Spitler L, Grossbard M, Ernstoff M et al.. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2000;18:16141621.

    • Search Google Scholar
    • Export Citation
  • 32

    Daud A, Mirza N, Lenox B et al.. Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. J Clin Oncol 2008;26:32353241.

    • Search Google Scholar
    • Export Citation
  • 33

    O’Day S, Hamid O, Urba W. Targeting CTLA-4: a novel strategy for the treatment of melanoma and other malignancies. Cancer 2007;110:26142627.

    • Search Google Scholar
    • Export Citation
  • 34

    Ribas A, Camacho L, Lopez-Berestein G et al.. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-CTLA-4 monoclonal antibody CP-675,206. J Clin Oncol 2005;23:89688977.

    • Search Google Scholar
    • Export Citation
  • 35

    Attia P, Phan G, Maker A et al.. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-CTLA-4. J Clin Oncol 2005;23:60436053.

    • Search Google Scholar
    • Export Citation
  • 36

    Ribas A, Hauschild A, Kefford R et al.. Phase III, open-label, randomized, comparative study of tremelimumab and chemotherapy (temozolomide or dacarbazine) in patients with advanced melanoma [abstract]. J Clin Oncol 2008;26:Abstract LBA9011.

    • Search Google Scholar
    • Export Citation
  • 37

    Weber J, Targan S, Scotland R et al.. Phase II trial of extended dose anti-CTLA-4 antibody ipilimumab with a multi-peptide vaccine for resected stages IIIC and IV melanoma [abstract]. J Clin Oncol 2006;24:Abstract 2510.

    • Search Google Scholar
    • Export Citation
  • 38

    Rosenberg S, Yang J, Restifo N. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909915.

  • 39

    Morton D, Mozzillo N, Thompson J et al.. An international, randomized, phase III trial of Bacillus Calmette-Guerin plus allogeneic melanoma vaccine or placebo after complete resection of melanoma metastatic to regional or distant sites [abstract]. J Clin Oncol 2007;25:Abstract 8508.

    • Search Google Scholar
    • Export Citation
  • 40

    Morton D, Foshag L, Hoon D et al.. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992;216:463482.

    • Search Google Scholar
    • Export Citation
  • 41

    Sondak V, Liu P, Tuthill R et al.. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 2002;20:20582066.

    • Search Google Scholar
    • Export Citation
  • 42

    Sondak V, Sosman J, Unger J et al.. Significant impact of HLA class I allele expression on outcome in melanoma patients treated with an allogeneic melanoma cell lysate vaccine. Final analysis of SWOG-9035 [abstract]. J Clin Oncol 2004;22:Abstract 7501.

    • Search Google Scholar
    • Export Citation
  • 43

    Berd D, Maguire H, Schuchter L et al.. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol 1997;15:23592370.

    • Search Google Scholar
    • Export Citation
  • 44

    Berd D, Sato T, Maguire H et al.. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol 2004;22:403415.

    • Search Google Scholar
    • Export Citation
  • 45

    Wallack M, Sivanandham M, Balch C et al.. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 1998;187:6979.

    • Search Google Scholar
    • Export Citation
  • 46

    Hersey P, Coates A, McCarthy W et al.. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol 2002;20:41814190.

    • Search Google Scholar
    • Export Citation
  • 47

    Gogas H, Kirkwood J, Sondak V. Chemotherapy for metastatic melanoma: time for a change? Cancer 2007;109:455464.

  • 48

    Hill G 2nd, Moss S, Golomb F et al.. DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) Surgical Adjuvant Study COG PROTOCOL 7040. Cancer 1981;47:25562562.

    • Search Google Scholar
    • Export Citation
  • 49

    Veronesi U, Adamus J, Aubert C et al.. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 1982;307:913916.

    • Search Google Scholar
    • Export Citation
  • 50

    Lejeune F, Macher E, Kleeberg U et al.. An assessment of DTIC vs. levamisole or placebo in the treatment of high risk stage I patients after surgical removal of a primary melanoma of the skin. A phase II adjuvant study (EORTC protocol 18761). Eur J Cancer 1988;24:881890.

    • Search Google Scholar
    • Export Citation
  • 51

    Karakousis C, Emrich L. Adjuvant treatment of malignant melanoma with DTIC + estracyt or BCG. J Surg Oncol 1987;36:235238.

  • 52

    Agarwala S, Keilholz U, Hogg D et al.. Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma [abstract]. J Clin Oncol 2007;25:Abstract 8510.

    • Search Google Scholar
    • Export Citation
  • 53

    Shah G, Coit D, Brady M et al.. Phase II trial of neoadjuvant temozolomide in advanced melanoma [abstract]. J Clin Oncol 2008;26:Abstract 9058.

  • 54

    Hwu W, Ivan D, Prieto V et al.. Randomized phase II neoadjuvant study of temozolomide alone or with pegylated interferon-alfa 2b in patients with resectable AJCC stage IIIC or stage IV (M1a) metastatic melanoma [abstract]. J Clin Oncol 2008;26:Abstract 20024.

    • Search Google Scholar
    • Export Citation
  • 55

    Richards JM, Mehta N, Ramming K et al.. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992;10:13381343.

  • 56

    Legha S, Ring S, Eton O et al.. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998;16:17521759.

    • Search Google Scholar
    • Export Citation
  • 57

    Atkins M, Hsu J, Lee S et al.. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, Interleukin-2 and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008;26:57485754.

    • Search Google Scholar
    • Export Citation
  • 58

    Curtin J, Fridlyand J, Kageshita T et al.. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:21352147.

  • 59

    Fecher L, Amaravadi R, Flaherty K. The MAPK pathway in melanoma. Curr Opin Oncol 2008;20:183189.

  • 60

    Fecher L. Overview of pathways in melanoma. In: Agarwala SS, Sondak VK, eds. Melanoma: Translational Research and Emerging Therapies. 1st ed. London: Informa Healthcare; 2008.

    • Search Google Scholar
    • Export Citation
  • 61

    Curtin J, Busam K, Pinkel D et al.. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24:43404346.

  • 62

    Wang W, Edington H, Jukic D et al.. Impact of IFNalpha2b upon pSTAT3 and the MEK/ERK MAPK pathway in melanoma. Cancer Immunol Immunother 2008;57:13151321.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 76 29 1
PDF Downloads 45 17 0
EPUB Downloads 0 0 0